-
Product Insights
Beta Upstream Project , Norway
Beta upstream project is located in North Sea, Norway. The upstream project is owned by Equinor Energy AS (60%); Sval Energi AS (20%); Var Energi ASA (20%). It will be operated by Equinor Energy AS. The project is currently in the announced stage and is expected to start operations in 2023. Beta Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rivogenlecleucel in Beta Thalassaemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rivogenlecleucel in Beta Thalassaemia Drug Details: Rivogenlecleucel (BPX-501) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SP-420 in Beta Thalassaemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SP-420 in Beta Thalassaemia Drug Details: SP-420 is under development for the treatment of transfusion...
-
Product Insights
Gombe Maria Beta Field, Gabon
Gombe Maria Beta upstream field is located in Ogooue Maritime, Gabon. The upstream field is owned by Perenco Gabon. It is operated by Perenco Gabon. The project started its operations in 1998. Gombe Maria Beta Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also...
-
Product Insights
New![]()
Net Present Value Model: Ascendis Pharma AS’s TransCon IL-2 beta/gamma
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Etavopivat in Beta Thalassaemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Etavopivat in Beta Thalassaemia Drug Details: Etavopivat (FT-4202) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Neuroblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Dinutuximab Beta in NeuroblastomaDrug Details:Dinutuximab beta (APN-311, Isqette, Qarziba) is a chimeric monoclonal antibody. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Thalagen in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Thalagen in Beta Thalassaemia Drug Details:Thalagen is under development for the treatment of beta-thalassemia and sickle...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sanguinate in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Sanguinate in Beta Thalassaemia Drug Details:Sanguinate is under development for the treatment sickle cell diseases (SCD)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Briquilimab in Beta Thalassaemia Drug Details:Briquilimab (AMG-191) is under development for the treatment of fanconi anemia, ...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sirolimus in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Sirolimus in Beta Thalassaemia Drug Details:Sirolimus is under development for the treatment of beta-cell thalassemia and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Leiomyosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Dinutuximab Beta in Leiomyosarcoma Drug Details:Dinutuximab beta (APN-311, Isqette, Qarziba) is a chimeric monoclonal antibody. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Exagamglogene Autotemcel in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Exagamglogene Autotemcel in Beta Thalassaemia Drug Details: Exagamglogene autotemcel (CTX-001) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SLN-124 in Beta Thalassaemia Drug Details: SLN-124 is under development for the treatment of hereditary hemochromatosis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Defibrotide Sodium in Beta Thalassaemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Defibrotide sodium in Beta Thalassaemia Drug Details: Defibrotide sodium (Noravid, Defitelio, Dinelasi, Prociclide) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BYC-103 in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BYC-103 in Beta Thalassaemia Drug Details:BYC-103 is under development for the treatment of beta thalassemia. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BD-211 in Beta Thalassaemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BD-211 in Beta Thalassaemia Drug Details: BD-211 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BEAM-101 in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BEAM-101 in Beta Thalassaemia Drug Details:BEAM-101 is under development for the treatment sickle cell disease and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EDIT-301 in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EDIT-301 in Beta Thalassaemia Drug Details:EDIT-301 is under development for the treatment of beta-thalassemia and sickle...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SCD-101 in Beta Thalassaemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCD-101 in Beta Thalassaemia Drug Details: SCD-101 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.